language_icon
EN
HI

Eris Lifesciences Share price

ERIS

1373.5

22.20 (-1.59%)
NSE
BSE
Last updated on 24 Apr, 2026 | 15:59 IST
Today's High

1416.30

Today's Low

1359.80

52 Week Low

1236.00

52 Week High

1910.00

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Eris Lifesciences Chart

Eris Lifesciences Share Key Metrics

Volume
1.41 L
Market Cap
19028.87 CR
LTQ@LTP
35@1373.50
ATP
1379.45
Var Margin
16.1 %
Circuit Range
1116.6-1674.8
Delivery %
42.21 %
Value
19.41 CR
ASM/GSM
No
Market Lot
1

Summary

Eris Lifesciences share price stands at ₹1373.5 at 24 Apr, 2026 | 15:59. The stock Eris Lifesciences intraday movement has stayed between ₹1359.80 and ₹1416.30, while on a 52-week basis it has fluctuated from ₹1236.00 to ₹1910.00.
In terms of trading activity, Eris Lifesciences has recorded a volume of 140742 shares. The Eris Lifesciences has a market cap of ₹138542887. The stock’s Average Traded Price (ATP) stands at ₹137945, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 35, 137350.
The Eris Lifesciences operates within a circuit range of ₹1116.6-1674.8 – ₹1116.6-1674.8, with a Value of ₹19.41 CR. The Delivery Percentage for the day is 42.21%. Additionally, Eris Lifesciences currently falls under the No framework, and trades with a market lot size of 1.

Eris Lifesciences Fundamentals

View More
P/E Ratio

44.16

P/B Ratio

5.26

Div. Yield

0.53

Sector P/E

63.82

Sector P/B

3.5

Sec. Div. Yield

0.57

Eris Lifesciences Resistance and Support

Pivot 1377.17

Resistance

First Resistance

1417.94

Second Resistance

1440.17

Third Resistance

1480.94

Support

First Support

1354.94

Second Support

1314.17

Third Support

1291.94

Eris Lifesciences Shareholding Pattern

View More
  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

54.86%

Mutual Fund

16.52%

Insurance

0.74%

Foreign Institutional Investors

8.36%

Domestic Institutional Investors

0.79%

Retail

18.72%

Others

0.01%

Total Promoters
MAR '24
54.9%
JUN '24
54.88%
SEP '24
54.87%
DEC '24
54.86%

Eris Lifesciences Corporate Actions

DateAgenda
2026-02-13Quarterly Results
2025-11-24Preferential issue of shares
2025-11-12Quarterly Results
2025-08-05Quarterly Results
2025-05-19Audited Results
2025-02-07Interim Dividend
2025-02-04Quarterly Results

Eris Lifesciences News

Eris Lifesciences Limited

Eris Lifesciences announced a postal ballot for the appointment of Mr. Vineet Varma as an Independent Director. His tenure is proposed for five years, from March 14, 2026, to March 13, 2031, with voting concluding on March 23, 2026.
Apr 23 2026 17:04:00

Eris Lifesciences Limited

Eris Lifesciences seeks shareholder approval via postal ballot to appoint Mr. Vineet Varma as an Independent Director for five years. The e-voting period commences on April 24, 2026, and concludes on May 23, 2026.
Apr 23 2026 17:04:00

Eris Lifesciences shares decline nearly 6% after observations issued for Swiss facilities

Eris Lifesciences' manufacturing facilities in Switzerland have received observations from the Croatian health regulator following an impact inspection, indicating potential compliance issues.
Apr 21 2026 15:04:00

Eris Lifesciences Limited

Eris Lifesciences' Swiss Parenterals units 1 & 2 received non-compliance observations from HALMED after a March 9-13, 2026 inspection. The company will address these procedural issues to reinstate approvals and ensure GMP compliance, though it might delay EU-CDMO product commercialization.
Apr 20 2026 22:04:00

Eris Lifesciences Ltd - 540596 - Closure Of The Transaction Related To Acquisition Of Probiotics Business Of Velbiom Probiotics Private Limited.

Eris Lifesciences announced the successful closure of its acquisition of the Probiotics Business of Velbiom Probiotics Private Limited. This finalizes the transaction previously intimated on March 20, 2026, marking a strategic entry into the probiotics segment.
Mar 31 2026 18:03:00

Eris Lifesciences Limited

Eris Lifesciences announced the successful closure of its acquisition of the probiotics business from Velbiom Probiotics Private Limited. This acquisition expands Eris's product portfolio, as previously intimated on March 20, 2026.
Mar 31 2026 18:03:00

Eris Lifesciences Ltd - 540596 - Corporate Guarantee

Eris Lifesciences Limited executed a corporate guarantee amounting to ₹75 crore for its wholly-owned subsidiary, Eris Bionxt Private Limited (EBPL). This guarantee secures a Term Loan sanctioned by HDFC Bank, which EBPL will use to repay its existing loan liabilities.
Mar 27 2026 16:03:00
Read More

About Eris Lifesciences

NSE : 21154  
BSE : 540596  
ISIN : INE406M01024  

The Company was incorporated as “Eris Lifescience Private Limited” on January 25 2007 as a private limited company under the Companies Act 1956 at Ahmedabad with a certificate of incorporation granted by the Registrar of Companies Gujarat Dadra and Nagar Haveli. Pursuant to a resolution of the Shareholders dated February 5 2007 the name of the Company was changed to “Eris Lifesciences Private Limited” and a fresh certificate of incorporation was issued by the Registrar of Companies Gujarat Dadra and Nagar Haveli on February 9 2007. Further pursuant to a conversion of the Company to a public limited company and as approved by the Shareholders through a resolution dated January 31 2017 the name was changed to “Eris Lifesciences Limited” and the RoC issued a fresh certificate of incorporation on February 2 2017.Major events and milestonesThe table below sets forth some of the major events in the history of the Company.2007-Incorporation of the Company-Launched “Eris” division focused on cardiology and diabetes segment2008-Launched “Nikkos” division focused on gastroenterology and orthopedics segment2009-Launched “Adura” division focused on cardiology and diabetes segment2011-Launched “Montana” division focused on gynecology and pediatrics segment2012-Launched “Inspira” division focused on cardiology segment2014-Launched “Victus” division focused on anti-diabetes segment-Set up Assam Facility by the Company2015-Launched “Eris 2” division focused on pain management segment2016-Acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now Aprica Pharmaceuticals Private Limited)-Acquired 100.00% of the outstanding equity shares of Aprica Healthcare Private Limited-Acquired 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited2017-Acquired the trademarks ‘UNION’ ‘REUNION’ and ‘BON UNION’Awards and Accreditations :2013-Awarded ‘Competitive Strategy Leadership’ award by Frost & Sullivan-Awarded ‘Emerging Companies Excellence’ award for scalability of business model and managing operational efficiencies by Business Today and Yes Bank

Read More

Eris Lifesciences Management

NamePosition
Milind TalegaonkarCompany Secretary & Compliance Officer
Krishnakumar VaidyanathanWhole Time Director & COO
View More

Eris Lifesciences FAQs

The Buying Price of Eris Lifesciences share is 1373.5 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Eris Lifesciences stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Eris Lifesciences, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Eris Lifesciences shares is 44.16. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Eris Lifesciences shares is 5.26. Useful to assess the stock's value relative to its book value.

To assess Eris Lifesciences’s valuation compare Sector P/E, P/B which are 63.82 & 3.5 with sector averages, along with growth rates and financial metrics.

The Market Cap of Eris Lifesciences is 19028.87 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Eris Lifesciences share price is 1910.00 & 1236.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Eris Lifesciences belongs to the Healthcare sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost